IndustryCompany release

McKesson raises FY2027 EPS guidance as second-quarter revenue reaches $111 billion

🇺🇸 Mckesson Corp (MCK) · Wed 04 Nov 2026

The US drug distributor also extended its CVS Health partnership to 2032, agreed to buy about 49% of Option Care Health and closed its Precision Medicine Group deal.

McKesson reported fiscal second-quarter results on 4 November 2026 for the period ended 30 September. Revenue was $111.0 billion, and adjusted earnings per share came in at $11.68, an increase of 18%.

The company lifted its full-year adjusted EPS guidance to a range of $45.60 to $46.40, up from the previous $44.20 to $45.00.

McKesson also announced several strategic moves. It has extended its distribution partnership with CVS Health through June 2032. It has also agreed to take a stake of roughly 49% in Option Care Health for about $1.4 billion, a transaction that still needs stockholder and regulatory approvals.

In addition, McKesson completed its acquisition of Precision Medicine Group on 2 November. No further financial or operational detail on the deals was available in the material reviewed.

What it means for your team

  • Market-access teams should note that the CVS Health distribution agreement now runs to June 2032, which gives a long horizon for one of the large US channel relationships.
  • The proposed Option Care Health stake remains subject to stockholder and regulatory approvals, so its timing and final terms are not yet settled.
  • Teams working with specialty and infusion channels or with real-world evidence providers may wish to watch how the Option Care and Precision Medicine Group transactions develop.

Company's press release (SEC filing): Mckesson Corp ↗

Article written by VigiEye from the official source (Mckesson Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →